DE68919229D1 - Hybride prokoagulierende proteine. - Google Patents

Hybride prokoagulierende proteine.

Info

Publication number
DE68919229D1
DE68919229D1 DE68919229T DE68919229T DE68919229D1 DE 68919229 D1 DE68919229 D1 DE 68919229D1 DE 68919229 T DE68919229 T DE 68919229T DE 68919229 T DE68919229 T DE 68919229T DE 68919229 D1 DE68919229 D1 DE 68919229D1
Authority
DE
Germany
Prior art keywords
proteins
hybrid
procoagulating
disclosed
peptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68919229T
Other languages
English (en)
Other versions
DE68919229T2 (de
Inventor
Randal Kaufman
Debra Pittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE68919229D1 publication Critical patent/DE68919229D1/de
Publication of DE68919229T2 publication Critical patent/DE68919229T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE68919229T 1988-11-14 1989-11-14 Hybride prokoagulierende proteine. Expired - Lifetime DE68919229T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/270,882 US5004803A (en) 1988-11-14 1988-11-14 Production of procoagulant proteins
PCT/US1989/005049 WO1990005530A1 (en) 1988-11-14 1989-11-14 Hybrid procoagulant proteins

Publications (2)

Publication Number Publication Date
DE68919229D1 true DE68919229D1 (de) 1994-12-08
DE68919229T2 DE68919229T2 (de) 1995-05-24

Family

ID=23033233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919229T Expired - Lifetime DE68919229T2 (de) 1988-11-14 1989-11-14 Hybride prokoagulierende proteine.

Country Status (7)

Country Link
US (1) US5004803A (de)
EP (1) EP0442961B1 (de)
JP (1) JPH04501508A (de)
AT (1) ATE113475T1 (de)
AU (1) AU4644689A (de)
DE (1) DE68919229T2 (de)
WO (1) WO1990005530A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0574402B2 (de) * 1990-11-26 2012-08-01 Genetics Institute, LLC Expression von pace in wirtszellen und verfahren zu dessen verwendung
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU5602394A (en) * 1992-11-13 1994-06-08 Duke University Chimeric blood coagulation proteins
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
WO1997003191A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
DK1754718T3 (da) 1996-04-24 2011-07-18 Univ Michigan Inaktiveringsresistent faktor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
US7090975B2 (en) 1998-03-13 2006-08-15 Promega Corporation Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection
US6335162B1 (en) 1998-03-13 2002-01-01 Promega Corporation Nucleic acid detection
US6235480B1 (en) 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
US6391551B1 (en) 1998-03-13 2002-05-21 Promega Corporation Detection of nucleic acid hybrids
US6312902B1 (en) 1998-03-13 2001-11-06 Promega Corporation Nucleic acid detection
US6270973B1 (en) 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US6703211B1 (en) 1998-03-13 2004-03-09 Promega Corporation Cellular detection by providing high energy phosphate donor other than ADP to produce ATP
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
WO2000024759A1 (en) * 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
CA2357011A1 (en) * 1999-02-18 2000-08-24 Promega Corporation Multiplex method for nucleic acid detection
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
HUE033158T2 (en) 2003-09-30 2017-11-28 Univ Pennsylvania Adeno-associated virus (AAV) clusters, sequences, vectors containing them, and their use
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
EP1866422B1 (de) 2005-04-07 2016-04-06 The Trustees of The University of Pennsylvania Methode um die funktion eines aav vektors zu erhöhen
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
EP2520586A1 (de) * 2006-06-30 2012-11-07 The Regents of the University of Michigan Verfahren zur Herstellung von Faktor-VIII-Proteinen durch Rekombinationsverfahren
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
CA3121739A1 (en) 2009-12-06 2011-06-09 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
JP5922095B2 (ja) 2010-03-29 2016-05-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 薬理学的に誘導される導入遺伝子アブレーション系
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
KR101956885B1 (ko) 2011-02-17 2019-03-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 조직 특이성 변경 및 ａａｖ９-매개 유전자 전달 개선을 위한 조성물 및 방법
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
JP2014522838A (ja) 2011-07-08 2014-09-08 バイオジェン アイデック ヘモフィリア インコーポレイテッド 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN108465106B (zh) 2012-01-12 2022-05-27 普吉特海湾血液中心 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
EA028309B1 (ru) 2012-01-12 2017-11-30 Байоджен Эмэй Инк. Полипептиды химерного фактора viii и их применение
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
EP3427744A1 (de) * 2013-03-15 2019-01-16 Bayer Healthcare LLC Variante faktor-viii-polypeptide sowie verfahren zu deren herstellung und verwendung
SI2968477T1 (sl) 2013-03-15 2020-04-30 Bioverativ Therapeutics Inc. Polipeptidne formulacije faktorja VIII
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
IL297611A (en) 2013-06-28 2022-12-01 Bioverativ Therapeutics Inc Binding of thrombin that degrades with castane and uses thereof
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP3082848B1 (de) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
EP4176894B1 (de) 2014-01-10 2024-02-28 Bioverativ Therapeutics Inc. Chimäre faktor-viii-proteine und ihre verwendungen
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
WO2022032140A2 (en) 2020-08-07 2022-02-10 Amicus Therapeutics, Inc. Vesicle targeting proteins and uses of same

Also Published As

Publication number Publication date
AU4644689A (en) 1990-06-12
WO1990005530A1 (en) 1990-05-31
EP0442961A1 (de) 1991-08-28
DE68919229T2 (de) 1995-05-24
US5004803A (en) 1991-04-02
EP0442961B1 (de) 1994-11-02
EP0442961A4 (en) 1992-04-08
JPH04501508A (ja) 1992-03-19
ATE113475T1 (de) 1994-11-15

Similar Documents

Publication Publication Date Title
DE68919229D1 (de) Hybride prokoagulierende proteine.
DE68929551D1 (de) Menschliche DNase
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
ES2147178T3 (es) Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
EA199801044A1 (ru) Модуляторы регенерации тканей
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
ATE294864T1 (de) Äusseres membranprotein von haemophilus
ATE239789T1 (de) Chimäre prokoagulierende proteine
DK215287D0 (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
ATE163013T1 (de) Alveolare oberflächenaktive proteine
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
DE3672950D1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
NO971059D0 (no) Modifiserte human-C3-proteiner
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE108830T1 (de) Dns-sequenzen, rekombinante dns-moleküle und verfahren zur herstellung menschlicher lipocortinähnlicher polypeptide.
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
EP0315081A3 (en) Anti-coagulating protein pp4-x, its preparation and use
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US